ARCHIVES

Rev/Vel/Dex Response Rate High In Phase I/II Study

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

Dalton To Head Moffitt Cancer Center; HHS Appoints Gerberding CDC Director

July 12, 2002

NCAB Subcommittee drafting Report Bioassay-Human Risk Relationship

February 16, 1979

Drug Company Cries Foul Over Clams Of Taxotere’s Superiority To Taxol

June 11, 1993

Study: Angiopoietin-2 Levels May Predict Lenvatinib Response

October 31, 2014

Upton May Leave NCI Soon, Newell Accepts Post At M.D. Anderson to Head Cancer Prevention

August 17, 1979

Bezwoda’s ’95 Phase II Study Entirely A Sham, Audit Finds.

April 27, 2001